The Role Of The MicroRNA Let 7 In Diabetic Proliferative Vascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$674,084.00
Summary
Cardiovascular complications remain the major cause of mortality in diabetes and our current treatment strategies are insufficient to reduce this burden. We have obtained extensive data to show that a novel molecule (the micro RNA, let 7b) has antiproliferative and vasculoprotective effects in diabetes. Thus, we propose that modulation of micro RNA let 7b specifically in vascular smooth muscle cells within the vascular wall represents a promising target to combat cardiovascular disease, in parti ....Cardiovascular complications remain the major cause of mortality in diabetes and our current treatment strategies are insufficient to reduce this burden. We have obtained extensive data to show that a novel molecule (the micro RNA, let 7b) has antiproliferative and vasculoprotective effects in diabetes. Thus, we propose that modulation of micro RNA let 7b specifically in vascular smooth muscle cells within the vascular wall represents a promising target to combat cardiovascular disease, in particular in diabetes.Read moreRead less
The Role Of Dicarbonyl-derived AGEs And RAGE In Diabetes Associated Atherosclerosis
Funder
National Health and Medical Research Council
Funding Amount
$470,617.00
Summary
Based on our pilot data we postulate that glucose derived molecules such as methylglyoxal (MGO) have effects on inflammation and oxidative stress leading to accelerated atherosclerosis in diabetes. Our studies aim to identify novel treatments which block these effects thus leading to superior protection and prevention of atherosclerosis in diabetes.
Epigenetic Determinants Of Nephropathy In Adults With Type 1 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$532,118.00
Summary
The prevention and successful management of diabetic complications are issues of utmost importance for the health of Australians. We hypothesize that epigenetic pathways partly determine why some individuals with diabetes develop complications of their disease, while others do not, despite a similar duration of diabetes, treatment intensity and mean glucose exposure.
ADVANCE-ON: A Post-trial Observational Study Of ADVANCE
Funder
National Health and Medical Research Council
Funding Amount
$775,867.00
Summary
The ADVANCE (Action in Diabetes and Vascular Disease) study demonstrasted that intensive control of blood glucose only reduced kidney disease but that control of blood pressure reduced both cardiovascular and kidney disease. This 10-year post-trial follow up study will determine whether intensive control of blood glucose exerts cardiovascular benefits that emerge in the long term in patients with type 2 diabetes.
Targeting Nicotinamide Adenine Dinucleotide Biosynthesis To Improve Metabolism
Funder
National Health and Medical Research Council
Funding Amount
$844,596.00
Summary
Nicotinamide adenine dinucleotide (NAD) is a cellular metabolite that regulates many biological processes. NAD levels decline with age and also in obesity and interventions that increase NAD levels produce favourable metabolic effects. In this proposal we will utilise a range of novel experimental models to define the molecular pathways that mediate the beneficial effects of NAD.
Development Of A Multi-faceted Diagnostic And Predictive Tool To Characterise Type Of Diabetes, Therapeutic Progression And Outcome
Funder
National Health and Medical Research Council
Funding Amount
$352,550.00
Summary
Diabetes is diagnosed using clinical assessment complemented by a few selected basic conventional laboratory tests. We plan to determine, in a representative community-based sample of Australian with diabetes, whether additional knowledge of genetic markers, diabetes-related antibody levels and tests of insulin secretory capacity adds to diagnosis of diabetes type, prediction of therapeutic progression over time, complications and death.
THE CYCLE OF OBESITY: Two Generations Of A Pregnancy Cohort To Investigate Obesity Epigenetics
Funder
National Health and Medical Research Council
Funding Amount
$1,117,795.00
Summary
Obesity has increased 3-5 fold in the last fifty years, overtaking smoking as the greatest killer. In recent history, each generation has experienced greater amounts of obesity and at younger ages. Being exposed in the womb to mother’s obesity transmits the risk to the child, possibly by changing our epigenetic profile and how our DNA code is read. We need to break this vicious cycle. This study is a world first, investigating 2 generations with respect to obesity and epigenetic profiles.
Does Enhanced Vitamin D Activity In Bone Heal The Skeleton In Disorders Of FGF23 Excess?
Funder
National Health and Medical Research Council
Funding Amount
$855,925.00
Summary
X-linked hypophosphatemia (XLH) is a genetic disorder which results in phosphate wasting and rickets. This severe disorder has no effective treatment. We have compelling new evidence that the rickets in XLH is not primarily a disorder of low blood phosphate, but rather specific issue of low cellular levels and activity of vitamin D (1,25D) within bone. This proposal is designed to specifically demonstrate this new concept and outline a new paradigm for a new XLH treatment.
Fenofibrate And Microvascular Events In Type 1 Diabetes (FAME 1) Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,883,529.00
Summary
Diabetes is one of the commonest cause of blindness in adults. Vision loss, which is irreversible, is a most feared complication of diabetes. A blood fat lowering drug called fenofibrate, available in Australia, has been shown to reduce eye damage in people with Type 2 diabetes by 35-40%, and to prevent eye damage in Type 1 diabetic animal models. This study will evaluate the potential benefits of fenofibrate in 450 adults with Type 1 diabetes who have early diabetic eye damage.
A Novel Role For Alzheimer Tau Protein In Insulin Secretion And Type 2 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$1,023,712.00
Summary
There is a strong association between type 2 diabetes and Alzheimer's disease, however the reason for this is not known. In Azheimer's disease a protein called tau does not function normally and contributes to the declining cognitive function. We have shown that when tau is absent, this lowers blood glucose and reduces the hallmark defects that contribute to type 2 diabetes. By understanding how tau works we may be able to provide better therapeutic agents to treat type 2 diabetes.